Low-dose fenfluramine in the treatment of neurologic disorders: Experience in Dravet syndrome

Therapeutic Advances in Neurological Disorders

Volumn 8, Issue 6, 2015, Pages 328-338

  Schoonjans, A Sofie ^a   Lagae, Lieven ^b   Ceulemans, Berten ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

childhood epilepsy; Dravet; drug resistance; fenfluramine; SCN1A; serotonin

Indexed keywords

ANOREXIGENIC AGENT; ANTICONVULSIVE AGENT; ANTIPYRETIC AGENT; BENZODIAZEPINE DERIVATIVE; CITALOPRAM; CLOBAZAM; CLONAZEPAM; DEXFENFLURAMINE; ETIRACETAM; FENFLURAMINE; FLUOXETINE; PAROXETINE; PHENTERMINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; STIRIPENTOL; TOPIRAMATE; VALPROIC ACID;

ABSENCE; ADD ON THERAPY; CARDIOVASCULAR DISEASE; DEPRESSION; DRUG TOLERABILITY; EPILEPSY; EPILEPTIC STATE; FEVER; FOCAL EPILEPSY; HUMAN; INTRACTABLE EPILEPSY; LOW DRUG DOSE; NEUROLOGIC DISEASE; NONHUMAN; PHOTOSENSITIVE EPILEPSY; PHOTOSENSITIVITY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SEIZURE; SEVERE MYOCLONIC EPILEPSY IN INFANCY; SIDE EFFECT; SOMNOLENCE; WEIGHT REDUCTION;

EID: 84945581601     PISSN: 17562856     EISSN: 17562864     Source Type: Journal    
DOI: 10.1177/1756285615607726     Document Type: Review

References (75)

1. Abenhaim L. Moride Y. Brenot F. Rich S. Benichou J. Kurz X. et al. (1996) Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med 335: 609–616.
2. Aicardi J. Gastaut H. (1985) Treatment of self-induced photosensitive epilepsy with fenfluramine. N Engl J Med 313: 1419.
3. Aicardi J. Gastaut H. Mises J. (1988) Syncopal attacks compulsively self-induced by Valsalva's maneuver associated with typical absence seizures. A case report. Arch Neurol 45: 923–925.
4. Bagdy G. Kecskemeti V. Riba P. Jakus R. (2007) Serotonin and epilepsy. J Neurochem 100: 857–873.
5. Barnes N. Sharp T. (1999) A review of central 5-HT receptors and their function. Neuropharmacology 38: 1083–1152.
6. Bender A. Morse R. Scott R. Holmes G. Lenck-Santini P. (2012) SCN1A mutations in Dravet syndrome: impact of interneuron dysfunction on neural networks and cognitive outcome. Epilepsy Behav 23: 177–186.
7. Berg A. Berkovic S. Brodie M. Buchhalter J. Cross J. van Emde Boas W. et al. (2010) Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 51: 676–685.
8. Boel M. Casaer P. (1996) Add-on therapy of fenfluramine in intractable self-induced epilepsy. Neuropediatrics 27: 171–173.
9. Bonnycastle D. Giarman N. Paasonen M. (1957) Anticonvulsant compounds and 5-hydroxytryptamine in rat brain. Br J Pharmacol Chemother 12: 228–231.
10. Brigo F. Storti M. (2013) Antiepileptic drugs for the treatment of severe myoclonic epilepsy in infancy. Cochrane Database Syst Rev 11: CD010483.
11. Brunklaus A. Dorris L. Zuberi S. (2011) Comorbidities and predictors of health-related quality of life in Dravet syndrome. Epilepsia 52: 1476–1482.
12. Brunklaus A. Ellis R. Reavey E. Forbes G. Zuberi S. (2012) Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome. Brain 135: 2329–2336.
13. Casaer P. Boel M. (2002) Fenfluramine as a potential antiepileptic drug. Epilepsia 43: 205–206.
14. Cestele S. Scalmani P. Rusconi R. Terragni B. Franceschetti S. Mantegazza M. (2008) Self-limited hyperexcitability: functional effect of a familial hemiplegic migraine mutation of the Nav1.1 (SCN1A) Na+ channel. J Neurosci 28: 7273–7283.
15. Ceulemans B. Boel M. Leyssens K. van Rossem C. Neels P. Jorens P. et al. (2012) Successful use of fenfluramine as an add-on treatment for Dravet syndrome. Epilepsia 53: 1131–1139.
16. Ceulemans B. Claes L. Lagae L. (2004) Clinical correlations of mutations in the SCN1A gene: from febrile seizures to severe myoclonic epilepsy in infancy. Pediatr Neurol 30: 236–243.
17. Chiron C. Dulac O. (2011) The pharmacologic treatment of Dravet syndrome. Epilepsia 52(Suppl. 2): 72–75.
18. Claes L. Del-Favero J. Ceulemans B. Lagae L. van Broeckhoven C. de Jonghe P. (2001) de novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 68: 1327–1332.
19. Clemens B. (1988) Dopamine agonist treatment of self-induced pattern-sensitive epilepsy. A case report. Epilepsy Res 2: 340–343.
20. Connolly H. Crary J. Mcgoon M. Hensrud D. Edwards B. Edwards W. et al. (1997) Valvular heart disease associated with fenfluramine–phentermine. N Engl J Med 337: 581–588.
21. Coppola G. Capovilla G. Montagnini A. Romeo A. Spano M. Tortorella G. et al. (2002) Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial. Epilepsy Res 49: 45–48.
22. Da Fonseca N. Joaquim H. Talib L. de Vincentiis S. Gattaz W. Valente K. (2015) Hippocampal serotonin depletion is related to the presence of generalized tonic–clonic seizures, but not to psychiatric disorders in patients with temporal lobe epilepsy. Epilepsy Res 111: 18–25.
23. Dailey J. Yan Q. Mishra P. Burger R. Jobe P. (1992) Effects of fluoxetine on convulsions and on brain serotonin as detected by microdialysis in genetically epilepsy-prone rats. J Pharmacol Exp Ther 260: 533–540.
24. Depienne C. Bouteiller D. Keren B. Cheuret E. Poirier K. Trouillard O. et al. (2009) Sporadic infantile epileptic encephalopathy caused by mutations in PCDH 19 resembles Dravet syndrome but mainly affects females. PLoS Genet 5: e1000381.
25. Douglas J. Munro J. Kitchin A. Muir A. Proudfoot A. (1981) Pulmonary hypertension and fenfluramine. Br Med J (Clin Res Ed) 283: 881–883.
26. Dravet C. (2011) The core Dravet syndrome phenotype. Epilepsia 52(Suppl. 2): 3–9.
27. Dressler A. Trimmel-Schwahofer P. Reithofer E. Muhlebner A. Groppel G. Reiter-Fink E. et al. (2015) Efficacy and tolerability of the ketogenic diet in Dravet syndrome - comparison with various standard antiepileptic drug regimen. Epilepsy Res 109: 81–89.
28. Favale E. Audenino D. Cocito L. Albano C. (2003) The anticonvulsant effect of citalopram as an indirect evidence of serotonergic impairment in human epileptogenesis. Seizure 12: 316–318.
29. Favale E. Rubino V. Mainardi P. Lunardi G. Albano C. (1995) Anticonvulsant effect of fluoxetine in humans. Neurology 45: 1926–1927.
30. Filip M. Bader M. (2009) Overview on 5-HT receptors and their role in physiology and pathology of the central nervous system. Pharmacol Rep 61: 761–777.
31. Fuller R. Snoddy H. Robertson D. (1988) Mechanisms of effects of D-fenfluramine on brain serotonin metabolism in rats: uptake inhibition versus release. Pharmacol Biochem Behav 30: 715–721.
32. Gastaut H. (1984) [Efficacy of fenfluramine for the treatment of compulsive behavior disorders in psychotic children]. Presse Med 13: 2024–2025.
33. Gastaut H. Zifkin B. Rufo M. (1987) Compulsive respiratory stereotypies in children with autistic features: polygraphic recording and treatment with fenfluramine. J Autism Develop Disord 17: 391–406.
34. Gastaut H. Zifkin B. (1987) Antiepileptic effects of fenfluramine: pilot study. Ann Neuurol 22: 414–415 (abstract).
35. Genton P. (2000) When antiepileptic drugs aggravate epilepsy. Brain Dev 22: 75–80.
36. Gentsch K. Heinemann U. Schmitz B. Behr J. (2000) Fenfluramine blocks low-Mg2+-induced epileptiform activity in rat entorhinal cortex. Epilepsia 41: 925–928.
37. Giraud C. Treluyer J. Rey E. Chiron C. Vincent J. Pons G. et al. (2006) In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos 34: 608–611.
38. Guerrini R. Dravet C. Genton P. Belmonte A. Kaminska A. Dulac O. (1998) Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 39: 508–512.
39. Hamid H. Kanner A. (2013) Should antidepressant drugs of the selective serotonin reuptake inhibitor family be tested as antiepileptic drugs? Epilepsy Behav 26: 261–265.
40. Harkin L. Bowser D. Dibbens L. Singh R. Phillips F. Wallace R. et al. (2002) Truncation of the GABA(A)-receptor Gamma 2 subunit in a family with generalized epilepsy with febrile seizures plus. Am J Hum Genet 70: 530–536.
41. Hattori J. Ouchida M. Ono J. Miyake S. Maniwa S. Mimaki N. et al. (2008) A screening test for the prediction of Dravet syndrome before one year of age. Epilepsia 49: 626–633.
42. Hurst D. (1990) Epidemiology of severe myoclonic epilepsy of infancy. Epilepsia 31: 397–400.
43. Jobe P. Browning R. (2005) The serotonergic and noradrenergic effects of antidepressant drugs are anticonvulsant, not proconvulsant. Epilepsy Behav 7: 602–619.
44. Klein K. Theisen F. Knake S. Oertel W. Hebebrand J. Rosenow F. et al. (2008) Topiramate, nutrition and weight change: a prospective study. J Neurol Neurosurg Psych 79: 590–593.
45. Kroll-Seger J. Portilla P. Dulac O. Chiron C. (2006) Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics 37: 325–329.
46. Lee H. Chi C. Tsai C. Chen C. Wang C. (2015) Electroencephalographic features of patients with SCN1A-positive Dravet syndrome. Brain Dev 37: 599–611.
47. Li R. Serdula M. Williamson D. Bowman B. Graham D. Green L. (1999) Dose-effect of fenfluramine use on the severity of valvular heart disease among Fen–Phen patients with valvulopathy. Int J Obesity Related Metab Disord 23: 926–928.
48. Marini C. Scheffer I. Nabbout R. Mei D. Cox K. Dibbens L. et al. (2009) SCN1A duplications and deletions detected in Dravet syndrome: implications for molecular diagnosis. Epilepsia 50: 1670–1678.
49. Marini C. Scheffer I. Nabbout R. Suls A. de Jonghe P. Zara F. et al. (2011) The genetics of Dravet syndrome. Epilepsia 52(Suppl. 2): 24–29.
50. Meador K. (2014) Seizure reduction with fluoxetine in Dravet syndrome. Epilepsy Behav Case Rep 2: 54–56.
51. Meng H. Xu H.Q. Yu L. Lin G.W. He N. Su T. et al. (2015) The SCN1A mutation database: updating information and analysis of the relationships among genotype, functional alteration, and phenotype. Hum Mutat 36 (6): 573–80.
52. Mistry A. Thompson C. Miller A. Vanoye C. George A. Jr Kearney J. (2014) Strain- and age-dependent hippocampal neuron sodium currents correlate with epilepsy severity in Dravet syndrome mice. Neurobiol Dis 65: 1–11.
53. Mulley J. Scheffer I. Petrou S. Dibbens L. Berkovic S. Harkin L. (2005) SCN1A mutations and epilepsy. Hum Mutat 25: 535–542.
54. Munro J. Seaton D. Duncan L. (1966) Treatment of refractory obesity with fenfluramine. Br Med J 2: 624–625.
55. Nieto-Barrera M. Candau R. Nieto-Jimenez M. Correa A. Del Portal L. (2000) Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure 9: 590–594.
56. Ogiwara I. Miyamoto H. Morita N. Atapour N. Mazaki E. Inoue I. et al. (2007) Nav1.1 localizes to axons of parvalbumin-positive inhibitory interneurons: a circuit basis for epileptic seizures in mice carrying an SCN1A gene mutation. J Neurosci 27: 5903–5914.
57. Pasini A. Tortorella A. Gale K. (1996) The anticonvulsant action of fluoxetine in substantia nigra is dependent upon endogenous serotonin. Brain Res 724: 84–88.
58. Patino G. Claes L. Lopez-Santiago L. Slat E. Dondeti R. Chen C. et al. (2009) A functional null mutation of SCN1B in a patient with Dravet syndrome. J Neurosci 29: 10764–10778.
59. Quilichini P. Chiron C. Ben-Ari Y. Gozlan H. (2006) Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. Epilepsia 47: 704–716.
60. Rubinstein M. Westenbroek R. Yu F. Jones C. Scheuer T. Catterall W. (2015) Genetic background modulates impaired excitability of inhibitory neurons in a mouse model of Dravet syndrome. Neurobiol Dis 73: 106–117.
61. Scheffer I. (2012) Diagnosis and long-term course of Dravet syndrome. Eur J Paediatr Neurol 16(Suppl. 1): S5–S8.
62. Specchio L. Iudice A. Specchio N. La Neve A. Spinelli A. Galli R. et al. (2004) Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol 27: 133–136.
63. Specchio N. Balestri M. Trivisano M. Japaridze N. Striano P. Carotenuto A. et al. (2012) Electroencephalographic features in Dravet syndrome: five-year follow-up study in 22 patients. J Child Neurol 27: 439–444.
64. Striano P. Coppola A. Pezzella M. Ciampa C. Specchio N. Ragona F. et al. (2007) An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology 69: 250–254.
65. Suls A. Jaehn J. Kecskes A. Weber Y. Weckhuysen S. Craiu D. et al. (2013) de novo loss-of-function mutations in CHD 2 cause a fever-sensitive myoclonic epileptic encephalopathy sharing features with Dravet syndrome. Am J Hum Genet 93: 967–975.
66. Takayama R. Fujiwara T. Shigematsu H. Imai K. Takahashi Y. Yamakawa K. et al. (2014) Long-term course of Dravet syndrome: a study from an epilepsy center in Japan. Epilepsia 55: 528–538.
67. Trindade-Filho E. de Castro-Neto E. De A. Lima E. Scorza F. Amado D. et al. (2008) Serotonin depletion effects on the pilocarpine model of epilepsy. Epilepsy Res 82: 194–199.
68. Verbeek N. Wassenaar M. van Campen J. Sonsma A. Gunning B. Knoers N. et al. (2015) Seizure precipitants in Dravet syndrome: what events and activities are specifically provocative compared with other epilepsies? Epilepsy Behav 47: 39–44.
69. Weiss L. Escayg A. Kearney J. Trudeau M. Macdonald B. Mori M. et al. (2003) Sodium channels SCN1A, SCN2A and SCN3A in familial autism. Mol Psychiatry 8: 186–194.
70. Wolff M. Casse-Perrot C. Dravet C. (2006) Severe myoclonic epilepsy of infants (Dravet syndrome): natural history and neuropsychological findings. Epilepsia 47(Suppl. 2): 45–48.
71. Yakoub M. Dulac O. Jambaque I. Chiron C. Plouin P. (1992) Early diagnosis of severe myoclonic epilepsy in infancy. Brain Dev 14: 299–303.
72. Yan Q. Jobe P. Cheong J. Ko K. Dailey J. (1994) Role of serotonin in the anticonvulsant effect of fluoxetine in genetically epilepsy-prone rats. Naunyn Schmiedebergs Arch Pharmacol 350: 149–152.
73. Yu F. Mantegazza M. Westenbroek R. Robbins C. Kalume F. Burton K. et al. (2006) Reduced sodium current in GABAergic interneurons in a mouse model of severe myoclonic epilepsy in infancy. Nat Neurosci 9: 1142–1149.
74. Zamponi N. Passamonti C. Cappanera S. Petrelli C. (2011) Clinical course of young patients with Dravet syndrome after vagal nerve stimulation. Eur J Paediatr Neurol 15: 8–14.
75. Zhang Y. Kecskes A. Copmans D. Langlois M. Crawford A. Ceulemans B. et al. (2015) Pharmacological characterization of an antisense knockdown zebrafish model of Dravet syndrome: inhibition of epileptic seizures by the serotonin agonist fenfluramine. PloS ONE 10: e0125898.